Welcome to our dedicated page for Brainstorm Cell Therapeutics I news (Ticker: BCLI), a resource for investors and traders seeking the latest updates and insights on Brainstorm Cell Therapeutics I stock.
BrainStorm Cell Therapeutics Inc. (BCLI) generates a steady flow of news centered on its NurOwn® autologous stem cell platform for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). Company press releases highlight clinical milestones, regulatory interactions, financing developments, and scientific presentations that shape the outlook for its lead investigational therapy.
News coverage frequently focuses on clinical trial progress for NurOwn, including the completed Phase 3 ALS study and preparations for the Phase 3b ENDURANCE trial under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration. Updates describe FDA clearance to initiate the Phase 3b trial, submission of an IND amendment, listing of the study on ClinicalTrials.gov, and operational steps such as site activation and manufacturing readiness.
Investors and observers will also find data-driven announcements, such as survival results from BrainStorm’s Expanded Access Program in ALS and pharmacogenomic and biomarker analyses presented at scientific meetings. These releases detail how NurOwn-treated cohorts performed relative to published ALS survival estimates and discuss factors like the UNC13A genotype and cerebrospinal fluid biomarker pathways.
Additional news items cover regulatory and community developments, including the FDA’s consideration of a Citizen Petition requesting renewed review of NurOwn data, as well as BrainStorm’s engagement with the ALS community. Financial results and capital-raising activities are reported through quarterly earnings releases and 8-K filings, alongside information about promissory and convertible promissory notes.
Stock Titan’s BCLI news page aggregates these company-issued updates and related coverage, allowing readers to follow clinical, regulatory, scientific, and financing events that may influence BrainStorm’s development trajectory. For those tracking BCLI, this page offers a single location to review the latest disclosed information on NurOwn, ALS and MS programs, manufacturing partnerships, and listing status changes.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) will present a corporate and clinical overview at Biotech Showcase™ 2022, scheduled virtually on January 10-12 and 17-18. Ralph Kern, M.D., President and CMO, will lead the presentation, which will be pre-recorded for registered attendees. The company is notable for its NurOwn® technology, targeting neurodegenerative diseases. NurOwn® cells, derived from autologous stem cells, aim to deliver neurotrophic factors to affected areas to combat conditions like ALS. BrainStorm has completed significant trials, including a Phase 3 study in ALS and a Phase 2 trial in progressive MS.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) has announced an extension of the NurOwn® Expanded Access Protocol (EAP) for patients with neurodegenerative diseases, following FDA recommendations. Eligible participants who completed the Phase 3 NurOwn trial can now receive up to 3 additional doses, increasing the total to 9 doses. The decision was informed by new analysis and biomarkers from the Phase 3 study. This initiative aims to provide more treatment options and gather further data on long-term effects.
BrainStorm Cell Therapeutics (BCLI) announced the peer-reviewed publication of Phase 3 clinical data in Muscle and Nerve for its NurOwn® therapy aimed at ALS treatment. While the trial did not achieve statistical significance in its primary and secondary endpoints, analyses indicate a treatment effect in patients with less advanced disease. Key findings revealed larger treatment effects in these subgroups and significant biomarker improvements in neuroinflammation and neurodegeneration. The study reinforces the potential of NurOwn to provide clinical benefits for ALS patients and emphasizes the need for further evaluation.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) and Catalent (NYSE: CTLT) have finalized the technology transfer for manufacturing the autologous cellular therapy NurOwn® at Catalent's Houston facility. This collaboration began in 2020, aiming to ensure CGMP clinical supply in anticipation of regulatory approval for NurOwn, which targets ALS and other neurodegenerative diseases. Both companies express optimism about the manufacturing process, emphasizing the complexity of cellular therapies and their commitment to advancing the therapy toward commercialization.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced the presentation of biomarker data on its therapy NurOwn® at the 32nd International Symposium on ALS/MND from December 7-10, 2021. Dr. Robert Brown will deliver the presentation, focusing on how NurOwn targets multiple disease pathways in ALS. Key findings show significant cerebrospinal fluid (CSF) biomarker changes linked to clinical outcomes. These insights support NurOwn's potential as a novel therapy for ALS, highlighting the importance of targeting various disease pathways to enhance treatment efficacy.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) presented new analyses from its Phase 3 NurOwn trial targeting ALS at the ALS ONE Research Symposium. Despite the trial not meeting primary and secondary endpoints statistically, analyses suggest potential treatment effects in patients with less severe baseline ALS. Key findings indicated a higher responder rate for NurOwn in participants predicted to have longer survival. The company plans to share further results through peer-reviewed publications and is committed to advancing NurOwn's availability to ALS patients.
BrainStorm Cell Therapeutics (BCLI) announced Q3 2021 financial results, reporting a net loss of $5.3 million compared to $4.5 million a year earlier. Cash reserves decreased to $28 million. Progress was noted in advancing NurOwn for ALS and MS, with promising Phase 3 ALS biomarker data shared at the NEALS conference. Newly appointed executives aim to enhance growth strategies, and GMP approval was secured for expanded manufacturing capacity in Israel. The company remains focused on addressing the urgent needs of ALS patients.
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) has appointed Sidney A. Spector, MD, PhD, and Kim Thacker, MD, to key roles in Global Strategy and Medical Affairs, as part of its growth strategy. Additionally, Stacy Lindborg, PhD, becomes Chief Development Officer. These leadership changes aim to enhance the company's clinical development and regulatory affairs, particularly for the NurOwn® platform, which is under consideration for regulatory approval for treating neurodegenerative diseases. The company has completed pivotal Phase 3 trials for ALS and is expanding its portfolio.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) appointed Dr. Menghis Bairu to its Board of Directors effective October 28, 2021. Dr. Bairu, a physician and entrepreneur with extensive experience in biotechnology, expressed enthusiasm for contributing to BrainStorm's mission of developing therapies for neurodegenerative diseases. He is the founder and CEO of Proxenia Venture Partners and has held significant roles in various biotech firms, including leading major transactions worth billions. Meanwhile, Sankesh Abbhi will not stand for re-election at the upcoming annual shareholder meeting.
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced a conference call scheduled for November 15, 2021, at 8:00 a.m. ET to discuss third-quarter financial results and corporate updates. CEO Chaim Lebovits will lead the call, addressing shareholder inquiries following a financial performance overview. Participants can submit questions until November 14, 2021. The company continues to develop its NurOwn® MSC-NTF cellular therapy platform for neurodegenerative diseases, notably receiving Orphan Drug designation for treating ALS.